{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:05:23Z","timestamp":1794110723873,"version":"4.8.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100031160","name":"Cartesian Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100031160","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41591-025-04171-y","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:01:40Z","timestamp":1767963700000},"page":"1131-1141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0724-0210","authenticated-orcid":false,"given":"Tuan","family":"Vu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hacer","family":"Durmus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6135-035X","authenticated-orcid":false,"given":"Michael","family":"Rivner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-4951","authenticated-orcid":false,"given":"Sheetal","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ragole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bennett","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamatha","family":"Pasnoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chafic","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithila","family":"Vullaganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Peltier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3893-4920","authenticated-orcid":false,"given":"Gregory","family":"Sahagian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc H.","family":"Feinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Slanksy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Barnett-Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaeem","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Gwathmey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Badruddoja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafsa","family":"Kamboh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2578-3028","authenticated-orcid":false,"given":"Rachel N.","family":"Ruggerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4284-9283","authenticated-orcid":false,"given":"Renee R.","family":"Fedak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7936-447X","authenticated-orcid":false,"given":"C. Andrew","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Kurtoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Kalayoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6668-6928","authenticated-orcid":false,"given":"Christopher M.","family":"Jewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milos D.","family":"Miljkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Dimachkie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahseen","family":"Mozaffar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7136-8617","authenticated-orcid":false,"suffix":"Jr","given":"James F.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the MG-001 Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"4171_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.596981","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis, K. & Tzartos, S. J. Myasthenia gravis: autoantibody specificities and their role in MG management. Front. Neurol. 11, 596981 (2020).","journal-title":"Front. Neurol."},{"key":"4171_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser, L., Wlodarski, R., Rezania, K. & Soliven, B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J. Clin. Med. 10, 2235 (2021).","journal-title":"J. Clin. Med."},{"key":"4171_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cells8070671","volume":"8","author":"I Koneczny","year":"2019","unstructured":"Koneczny, I. & Herbst, R. Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture. Cells 8, 671 (2019).","journal-title":"Cells"},{"key":"4171_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-024-03553-y","volume":"24","author":"J McCallion","year":"2024","unstructured":"McCallion, J. et al. Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa. BMC Neurol. 24, 61 (2024).","journal-title":"BMC Neurol."},{"key":"4171_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","volume":"39","author":"L Gerischer","year":"2025","unstructured":"Gerischer, L., Doksani, P., Hoffmann, S. & Meisel, A. New and emerging biological therapies for myasthenia gravis: a focussed review for clinical decision-making. BioDrugs 39, 185\u2013213 (2025).","journal-title":"BioDrugs"},{"key":"4171_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686466","volume":"12","author":"C Zografou","year":"2021","unstructured":"Zografou, C., Vakrakou, A. G. & Stathopoulos, P. Short- and long-lived autoantibody-secreting cells in autoimmune neurological disorders. Front. Immunol. 12, 686466 (2021).","journal-title":"Front. Immunol."},{"key":"4171_CR7","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit, V. et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol. 22, 578\u2013590 (2023).","journal-title":"Lancet Neurol."},{"key":"4171_CR8","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1016\/j.ymthe.2025.06.029","volume":"33","author":"S Schreiber","year":"2025","unstructured":"Schreiber, S. et al. Effective use of BCMA-targeting bispecific T cell-engaging antibody in treatment-refractory LRP4+ myasthenia gravis. Mol. Ther. 33, 4130\u20134134 (2025).","journal-title":"Mol. Ther."},{"key":"4171_CR9","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s44321-024-00043-z","volume":"16","author":"D-S Tian","year":"2024","unstructured":"Tian, D.-S. et al. B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis. EMBO Mol. Med. 16, 966\u2013987 (2024).","journal-title":"EMBO Mol. Med."},{"key":"4171_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061597","volume":"11","author":"MK Alhaidar","year":"2022","unstructured":"Alhaidar, M. K., Abumurad, S., Soliven, B. & Rezania, K. Current treatment of myasthenia gravis. J. Clin. Med. 11, 1597 (2022).","journal-title":"J. Clin. Med."},{"key":"4171_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","volume":"24","author":"C Antozzi","year":"2025","unstructured":"Antozzi, C. et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 24, 105\u2013116 (2025).","journal-title":"Lancet Neurol."},{"key":"4171_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril, V. et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 22, 383\u2013394 (2023).","journal-title":"Lancet Neurol."},{"key":"4171_CR13","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr.","year":"2021","unstructured":"Howard, J. F. Jr. et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 20, 526\u2013536 (2021).","journal-title":"Lancet Neurol."},{"key":"4171_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1277596","volume":"14","author":"PP San","year":"2023","unstructured":"San, P. P. & Jacob, S. Role of complement in myasthenia gravis. Front. Neurol. 14, 1277596 (2023).","journal-title":"Front. Neurol."},{"key":"4171_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1275533","volume":"14","author":"A Vesperinas-Castro","year":"2023","unstructured":"Vesperinas-Castro, A. & Cort\u00e9s-Vicente, E. Rituximab treatment in myasthenia gravis. Front. Neurol. 14, 1275533 (2023).","journal-title":"Front. Neurol."},{"key":"4171_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr.","year":"2023","unstructured":"Howard, J. F. Jr. et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 22, 395\u2013406 (2023).","journal-title":"Lancet Neurol."},{"key":"4171_CR17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr.","year":"2017","unstructured":"Howard, J. F. Jr. et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 16, 976\u2013986 (2017).","journal-title":"Lancet Neurol."},{"key":"4171_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020282","volume":"17","author":"A Bangolo","year":"2025","unstructured":"Bangolo, A. et al. Comprehensive review of early and late toxicities in CAR T-cell therapy and bispecific antibody treatments for hematologic malignancies. Cancers (Basel) 17, 282 (2025).","journal-title":"Cancers (Basel)"},{"key":"4171_CR19","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41591-025-03813-5","volume":"31","author":"K Rejeski","year":"2025","unstructured":"Rejeski, K., Hill, J. A., Dahiya, S. & Jain, M. D. Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nat. Med. 31, 2132\u20132146 (2025).","journal-title":"Nat. Med."},{"key":"4171_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01191-8","volume":"14","author":"D Swan","year":"2024","unstructured":"Swan, D., Madduri, D. & Hocking, J. CAR-T cell therapy in multiple myeloma: current status and future challenges. Blood Cancer J. 14, 206 (2024).","journal-title":"Blood Cancer J."},{"key":"4171_CR21","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41375-020-0951-5","volume":"35","author":"L Lin","year":"2021","unstructured":"Lin, L. et al. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia 35, 752\u2013763 (2021).","journal-title":"Leukemia"},{"key":"4171_CR22","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1002\/acn3.70167","volume":"12","author":"N Chahin","year":"2025","unstructured":"Chahin, N. et al. Durability of response to B-cell maturation antigen-directed mRNA cell therapy in myasthenia gravis. Ann. Clin. Transl. Neurol. 12, 2358\u20132366 (2025).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"4171_CR23","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mus.23330","volume":"45","author":"M Benatar","year":"2012","unstructured":"Benatar, M. et al. Recommendations for myasthenia gravis clinical trials. Muscle Nerve 45, 909\u2013917 (2012).","journal-title":"Muscle Nerve"},{"key":"4171_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04170-z","author":"RR Fedak","year":"2026","unstructured":"Fedak, R. R. et al. BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-025-04170-z (2026).","journal-title":"Nat. Med."},{"key":"4171_CR25","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1182\/blood.2024025413","volume":"145","author":"D Mougiakakos","year":"2025","unstructured":"Mougiakakos, D., Meyer, E. H. & Schett, G. CAR T cells in autoimmunity: game changer or stepping stone? Blood 145, 1841\u20131849 (2025).","journal-title":"Blood"},{"key":"4171_CR26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","volume":"20","author":"G Schett","year":"2024","unstructured":"Schett, G. et al. Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nat. Rev. Rheumatol. 20, 531\u2013544 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"4171_CR27","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia, A. et al. Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol. 22, 1104\u20131105 (2023).","journal-title":"Lancet Neurol."},{"key":"4171_CR28","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1136\/ard-2024-226017","volume":"83","author":"A Haghikia","year":"2024","unstructured":"Haghikia, A. et al. Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Ann. Rheum. Dis. 83, 1597\u20131598 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"4171_CR29","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 28, 2124\u20132132 (2022).","journal-title":"Nat. Med."},{"key":"4171_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado2084","volume":"16","author":"EP English","year":"2024","unstructured":"English, E. P. et al. Engineering CAR-T therapies for autoimmune disease and beyond. Sci. Transl. Med. 16, eado2084 (2024).","journal-title":"Sci. Transl. Med."},{"key":"4171_CR31","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1182\/bloodadvances.2024015634","volume":"9","author":"AP Chung","year":"2025","unstructured":"Chung, A. P. et al. Inequalities in CAR T-cell therapy access for US patients with relapsed\/refractory DLBCL: a SEER\u2013Medicare data analysis. Blood Adv. 9, 4727\u20134735 (2025).","journal-title":"Blood Adv."},{"key":"4171_CR32","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1080\/10428194.2025.2513003","volume":"66","author":"MS Odstrcil Bobillo","year":"2025","unstructured":"Odstrcil Bobillo, M. S., McClune, B. & Couriel, D. R. Access barriers to hematopoietic stem cell transplantation and CAR T-cells in US. Leuk. Lymphoma 66, 1969\u20131979 (2025).","journal-title":"Leuk. Lymphoma"},{"key":"4171_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1247931","volume":"11","author":"T Hughes","year":"2023","unstructured":"Hughes, T. et al. The economic burden of individuals living with generalized myasthenia gravis and facing social determinants of health challenges. Front. Public Health 11, 1247931 (2023).","journal-title":"Front. Public Health"},{"key":"4171_CR34","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","volume":"74","author":"TM Burns","year":"2010","unstructured":"Burns, T. M., Conaway, M. & Sanders, D. B.; MG Composite and MG-QOL15 Study Group. The MG Composite: a valid and reliable outcome measure for myasthenia gravis. Neurology 74, 1434\u20131440 (2010).","journal-title":"Neurology"},{"key":"4171_CR35","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.23944","volume":"49","author":"DB Sanders","year":"2014","unstructured":"Sanders, D. B. et al. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve 49, 483\u2013486 (2014).","journal-title":"Muscle Nerve"},{"key":"4171_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2203","volume":"11","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: a systematic retrospective study involving 67 patients. Brain Behav. 11, e02203 (2021).","journal-title":"Brain Behav."},{"key":"4171_CR37","volume":"2002","author":"P Gajdos","year":"2002","unstructured":"Gajdos, P., Chevret, S. & Toyka, K. Plasma exchange for myasthenia gravis. Cochrane Database Syst. Rev. 2002, CD002275 (2002).","journal-title":"Cochrane Database Syst. Rev."},{"key":"4171_CR38","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/WCO.0000000000001196","volume":"36","author":"F Vanoli","year":"2023","unstructured":"Vanoli, F. & Mantegazza, R. Current drug treatment of myasthenia gravis. Curr. Opin. Neurol. 36, 410\u2013415 (2023).","journal-title":"Curr. Opin. Neurol."},{"key":"4171_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1573-2","volume":"19","author":"ED Bacci","year":"2019","unstructured":"Bacci, E. D., Coyne, K. S., Poon, J.-L., Harris, L. & Boscoe, A. N. Understanding side effects of therapy for myasthenia gravis and their impact on daily life. BMC Neurol. 19, 335 (2019).","journal-title":"BMC Neurol."},{"key":"4171_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0332073","volume":"20","author":"C Carrillo Infante","year":"2025","unstructured":"Carrillo Infante, C. & Mujeebuddin, A. Eculizumab and ravulizumab clinical trial and real-world pharmacovigilance of meningococcal infections across indications. PLoS ONE 20, e0332073 (2025).","journal-title":"PLoS ONE"},{"key":"4171_CR41","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","volume":"130","author":"M Konar","year":"2017","unstructured":"Konar, M. & Granoff, D. M. Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults. Blood 130, 891\u2013899 (2017).","journal-title":"Blood"},{"key":"4171_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127473","volume":"62","author":"BM Greenberg","year":"2025","unstructured":"Greenberg, B. M. et al. SARS-CoV-2 vaccine failure rates and predictors of immune response in a diverse immunocompromised patient population. Vaccine 62, 127473 (2025).","journal-title":"Vaccine"},{"key":"4171_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf383","author":"JS Little","year":"2025","unstructured":"Little, J. S. et al. Protracted SARS-CoV-2 infection in B-cell depleted patients: immunologic and viral characteristics and response to dual and extended antiviral therapy. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaf383 (2025).","journal-title":"Clin. Infect. Dis."},{"key":"4171_CR44","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/1744666X.2025.2497840","volume":"21","author":"KG Gwathmey","year":"2025","unstructured":"Gwathmey, K. G. et al. Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases. Expert Rev. Clin. Immunol. 21, 627\u2013638 (2025).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"4171_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-095652","volume":"15","author":"Y Ju","year":"2025","unstructured":"Ju, Y. & Qin, X. Postmarketing adverse events of efgartigimod alfa: a real-world pharmacovigilance study based on the FAERS database. BMJ Open 15, e095652 (2025).","journal-title":"BMJ Open"},{"key":"4171_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2025.2490063","volume":"25","author":"H Teranishi","year":"2025","unstructured":"Teranishi, H., Tsuda, K., Kanzaki, R., Hayashi, T. & Harada, D. Safety and effectiveness of efgartigimod for intravenous infusion in patients with generalized myasthenia gravis: an interim analysis of Japanese post-marketing surveillance. Expert Opin. Biol. Ther. 25, 1\u20138 (2025).","journal-title":"Expert Opin. Biol. Ther."},{"key":"4171_CR47","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"4171_CR48","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4171_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl5197","volume":"376","author":"C Dom\u00ednguez Conde","year":"2022","unstructured":"Dom\u00ednguez Conde, C. et al. Cross-tissue immune cell analysis reveals tissue-specific features in humans. Science 376, eabl5197 (2022).","journal-title":"Science"},{"key":"4171_CR50","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.clim.2006.09.001","volume":"122","author":"J Kim","year":"2007","unstructured":"Kim, J., Hayton, W. L., Robinson, J. M. & Anderson, C. L. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin. Immunol. 122, 146\u2013155 (2007).","journal-title":"Clin. Immunol."},{"key":"4171_CR51","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 3321\u20133330 (2016).","journal-title":"Blood"},{"key":"4171_CR52","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"4171_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1422591","volume":"15","author":"J Li","year":"2024","unstructured":"Li, J. et al. Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention. Front. Immunol. 15, 1422591 (2024).","journal-title":"Front. Immunol."},{"key":"4171_CR54","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1016\/j.ymthe.2024.03.030","volume":"32","author":"DN Biery","year":"2024","unstructured":"Biery, D. N., Turicek, D. P., Diorio, C., Schroeder, B. A. & Shah, N. N. Need for standardization of cytokine profiling in CAR T cell therapy. Mol. Ther. 32, 2979\u20132983 (2024).","journal-title":"Mol. Ther."},{"key":"4171_CR55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.exphem.2020.07.003","volume":"88","author":"T Pabst","year":"2020","unstructured":"Pabst, T. et al. Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome. Exp. Hematol. 88, 7\u201314 (2020).","journal-title":"Exp. Hematol."},{"key":"4171_CR56","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664\u2013679 (2016).","journal-title":"Cancer Discov."},{"key":"4171_CR57","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2326-6066.CIR-13-0006","volume":"1","author":"MV Maus","year":"2013","unstructured":"Maus, M. V. et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1, 26\u201331 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"4171_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0756-3","volume":"16","author":"T Akaishi","year":"2016","unstructured":"Akaishi, T. et al. Response to treatment of myasthenia gravis according to clinical subtype. BMC Neurol. 16, 225 (2016).","journal-title":"BMC Neurol."},{"key":"4171_CR59","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mus.21462","volume":"41","author":"Y Nagane","year":"2010","unstructured":"Nagane, Y., Suzuki, S., Suzuki, N. & Utsugisawa, K. Factors associated with response to calcineurin inhibitors in myasthenia gravis. Muscle Nerve 41, 212\u2013218 (2010).","journal-title":"Muscle Nerve"},{"key":"4171_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13367-8","volume":"272","author":"W Zhu","year":"2025","unstructured":"Zhu, W. et al. Factors associated with early response to efgartigimod in patients with generalized myasthenia gravis: a multicenter retrospective observational study. J. Neurol. 272, 622 (2025).","journal-title":"J. Neurol."},{"key":"4171_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00776","volume":"11","author":"ML Fichtner","year":"2020","unstructured":"Fichtner, M. L., Jiang, R., Bourke, A., Nowak, R. J. & O\u2019Connor, K. C. Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front. Immunol. 11, 776 (2020).","journal-title":"Front. Immunol."},{"key":"4171_CR62","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200436","volume":"12","author":"F Khani-Habibabadi","year":"2025","unstructured":"Khani-Habibabadi, F. et al. AChR autoantibody pathogenic properties are heterogeneously distributed and undergo temporal changes among patients with myasthenia gravis. Neurol. Neuroimmunol. Neuroinflamm. 12, e200436 (2025).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"4171_CR63","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","volume":"146","author":"MC Pham","year":"2023","unstructured":"Pham, M. C. et al. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol. 146, 319\u2013336 (2023).","journal-title":"Acta Neuropathol."},{"key":"4171_CR64","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1056\/NEJMc2509522","volume":"393","author":"Q Wang","year":"2025","unstructured":"Wang, Q. et al. In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. N. Engl. J. Med. 393, 1542\u20131544 (2025).","journal-title":"N. Engl. J. Med."},{"key":"4171_CR65","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi, S. et al. Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve 65, 630\u2013639 (2022).","journal-title":"Muscle Nerve"},{"key":"4171_CR66","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","volume":"841","author":"RJ Barohn","year":"1998","unstructured":"Barohn, R. J. et al. Reliability testing of the quantitative myasthenia gravis score. Ann. N. Y. Acad. Sci. 841, 769\u2013772 (1998).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"4171_CR67","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.21883","volume":"43","author":"TM Burns","year":"2011","unstructured":"Burns, T. M. et al. The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. Muscle Nerve 43, 14\u201318 (2011).","journal-title":"Muscle Nerve"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04171-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04171-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04171-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T15:02:46Z","timestamp":1774018966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04171-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,9]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4171"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04171-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,9]]},"assertion":[{"value":"27 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.K., R.N.R., R.R.F., C.A.S., M. Kurtoglu, M. Kalayoglu, M.S., C.M.J. and M.D.M. are employees of and\/or hold equity in Cartesian Therapeutics. C.M.J. is appointed as a professor at the University of Maryland and as a Research Health Scientist at the VA Maryland Health Care System. The views in this paper do not reflect the views of the state of Maryland or the US government. C.M.J. is a founder of Nodal Therapeutics and Patch Bio and holds equity positions with Nodal Therapeutics, Patch Bio, Aletira Therapeutics and Barinthus Biotherapeutics. C.B.-T. has served as a member of the advisory board for argenx, Alexion, UCB, Janssen and NMD Pharma. She has been a consultant for argenx, Janssen, Novartis and UCB. She has received research support from the US Department of Defense, Muscular Dystrophy Canada and MGNet. She is the primary developer of the Myasthenia Gravis Impairment Index (MGII) and may receive royalties. T.V. is a site principal investigator at the University of South Florida for myasthenia gravis clinical trials sponsored by Alexion\/AstraZeneca, argenx, Amgen, Cartesians, COUR, Dianthus, EMD Serono, Johnson & Johnson, Immunovant, NMD Pharma, Regeneron and UCB. T.V. received speaking and\/or consulting honoraria related to myasthenia gravis from Alexion, Amgen, argenx, Dianthus and Johnson & Johnson. T.M. has received research funding from the Muscular Dystrophy Association and the National Institutes for Health (R01AR074457, UM1TR004927, R21AR082649, UO1NS139215 and f T32AR083870). T.M. has received research funding from the following sponsors: Alexion, Amicus, AnnJi, Argenx, Aro Bio, Ask Bio, Audentes (now Astellas Gene Therapy), Cabaletta, Cartesian Therapeutics, Fate Therapeutics, ML-Bio, Momenta, NKarta, Ra Pharmaceuticals, Sanofi, Spark Therapeutics and Valerion. T.M. has served as a consultant for Alexion, Amicus, AnnJi, Argenx, Aro Bio, Arvinas, Ask Bio, Astellas Gene Therapeutics, AvroBio, BioCryst, Cabaletta, Creyon, Dyne, Fate Therapeutics, Horizon Therapeutics, Immunovant, Maze Therapeutics, Merck, Poseida, Regeneron, Shionogi, Momenta (now Janssen), Sanofi, UCB and Variant Bio. T.M. serves on the medical advisory board for the Myositis Association and the Neuromuscular Disease Foundation. He serves on the data safety monitoring board for Acceleron, Applied Therapeutics (Chair), Avidity, Sarepta, Sirolimus in IBM trial (Chair) and the NI. J.F.H. discloses research funding (paid to his institution) from Ad Scientiam, Alexion AstraZeneca Rare Disease, argenx, Cartesian Therapeutics, Centers for Disease Control and Prevention, Merck EMD Serono, MGFA, Muscular Dystrophy Association, NIH, NMD Pharma and UCB Bioscience; honoraria\/consulting fees from AcademicCME, Alexion AstraZeneca Rare Disease, Amgen, argenx, Biohaven Ltd, Cartesian Therapeutics, CheckRare CME, CoreEvitas, Curie.bio, H. Lundbeck A\/S, Japan Tobacco Company, Merck EMB Serono, NMD Pharma, Novartis Pharma, PeerView CME, Physicians\u2032 Education Resource (PER) CME, PlatformQ CME, Regeneron Pharmaceuticals, Seismic Therapeutics, TG Therapeutics, Toleranzia AB and UCB Pharma. H.D. has served as a speaker and consultant for Alexion\/AstraZeneca and UCB. K.G. received speaking honoraria (remotely) for Alexion \/AstraZebeca and Argenx, consulting honoraria for Alexion\/AstraZeneca, Amgen, Novartis and UCB. She also served as a DSMB member for Cabaletta and Cour. C.K. served as a consultant and\/or on an advisory board for Acceleron, Alpine, Alexion\/AstraZeneca, Alnylam, Amgen, Amicus, Annexon, Applied Therapeutics, Argenx, Catalyst, Corino, Biogen, CSL Behring, Genentech, Immunovant, Intellia, Ionis, J&J, Medison, Neuroderm, Novo Nordisk, Nuvig, Octapharma, Pfizer, Sanofi, UCB, Takeda, Vertex and Zai Lab. S.S. served as a speaker and\/or consultant for UCB, Argenx and Astra Zeneca. G. Sahagian has received funding as an Investigator for clinical trials sponsored by Argenx, Sanofi, Lilly, Biogen, Cartesian, Immunovant, NMD Pharma, Regeneron and UCB. He received speaking and\/or consulting honoraria from Alexion\/AstraZeneca, Amgen, Argenx, Biogen, Cartesian and Immunovant. M.D received consultancy fees, payment or honoraria for lectures, presentations, manuscript writing or educational events, and participated on a Data Safety Monitoring Board or Advisory Board for Abcuro, Amicus, Annexon, ArgenX, Astellas, Cabaletta Bio, Catalyst, Covance\/Labcorp\/Fortrea, CSL-Behring, Creyon Bio, Inc., Dianthus, EMD Serono\/Merck, Horizon, Ig Society, Inc, Janssen, Medlink, Nuvig, Octapharma, Sanofi Genzyme, Shire Takeda and TACT\/Treat NMD and Vertex. M.M.D. has received grants or from Abcuro, Alexion\/ AstraZeneca, Alnylam Pharmaceuticals, Amicus, ArgenX, Biosensics, Bristol-Myers Squibb, Cabaletta Bio, Catalyst, CSL-Behring, EMD Serono, FDA\/OOPD, GlaxoSmithKline, Genentech, Grifols, Horizon Immnunovant, Mitsubishi Tanabe Pharma, MDA, NIH, Nkarta, Novartis, Octapharma, Orphazyme, Priovant, Ra Pharma\/UCB Biopharma, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics and The Myositis Association. M.D. received royalty for manuscript writing from Wolters Kluwer Health\/UpToDate and from Elsevier and for discovery relating to health care from Zevra Therapeutics. Z.S. has served as member of the advisory boards or Site Principal Investigator for clinical trials sponsored by Argenx, Alexion\/AstraZeneca, UCB, Janssen, CSL Behring, Takeda, Regeneron, Immunovant, Novartis and Pfizer. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}